drug

AAV

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about AAV: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

19Connections
1Hypotheses
3Analyses
18Outgoing
0Incoming

No summary available yet. View on Wiki →

💊 Drug Info
NameAAV
SummaryChina-based biotechnology company developing AAV gene therapies for rare neurological diseases, with a CDKL5 deficiency program in IND-enabling stage.
Key Genes/ProteinsNDNF, BDNF, APOE, GDNF, Cas9
Related DiseasesRodents, Macaque
Related PathwaysDescending Motor Pathways
Linked Hypotheses1 hypotheses

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Vigonvita Sciences

company · 555 words

cbs-psp-daily-action-plan

therapeutic · 30834 words

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

Corticobasal Syndrome (CBS)

disease · 11374 words

Pathway Diagram

graph TD
    AAV["AAV"] -->|"associated"| Rodents["Rodents"]
    style Rodents fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    AAV["AAV"] -->|"associated"| Macaque["Macaque"]
    style Macaque fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    AAV["AAV"] -->|"targets"| NDNF["NDNF"]
    style NDNF fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    AAV["AAV"] -->|"targets"| Brain["Brain"]
    style Brain fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    AAV["AAV"] -->|"transports"| BDNF["BDNF"]
    style BDNF fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    AAV["AAV"] -->|"transports"| APOE["APOE"]
    style APOE fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
    AAV["AAV"] -->|"transports"| GDNF["GDNF"]
    style GDNF fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    style AAV fill:#1b5e20,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold

Outgoing (19)

TargetRelationTypeStr
Rodentsassociated_withphenotype0.90
Macaqueassociated_withphenotype0.90
NDNFtargetsprotein0.90
Rodentsexpressed_inphenotype0.90
Macaqueexpressed_inphenotype0.90

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
TREM2 R47H Variant Correction — AAV-Mediated Rescue of Commo 0.452 Alzheimer's disease TREM2 agonism vs antagonism in DAM micro

Mentioning Analyses (3)

Scientific analyses that reference this entity

What delivery mechanisms can achieve therapeutically relevant CRISPR concentrati

drug delivery | 2026-04-10 | 0 hypotheses

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-03 | 14 hypotheses Top: 0.622

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-02 | 0 hypotheses

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213] Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei Neuron 2026 0
Role of TREM2 in neuroinflammation. [PMID:41213496] Abdulkhaliq AA, Alasiri G, Almoghrabi Y, Exp Neurol 2026 0
Synergistic potential of TREM2 agonists and exercise training in Alzheimer's dis [PMID:41494649] Zhang J, St Pierre Schneider B, Muguerza Am J Physiol Endocrinol Metab 2026 0
Diankuang Mengxing Decoction exerts neuroprotective effects in post-stroke depre [PMID:41534750] Yang X, Zhao Y, Liu W, Feng J, Wu X et a J Ethnopharmacol 2026 0
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvir [PMID:41576929] Mateus-Tique J, Lakshmi A, Singh B, Iyer Cancer Cell 2026 0
Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] Li X, Tang X, Zeng J, Duan L, Hou Z et a Cell 2026 0
TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393] Feiten AF, Dahm K, Schlepckow K, van Len Nat Commun 2026 0
Large-scale single-cell analysis and in silico perturbation reveal dynamic evolu [PMID:41617928] Xia P, Shuang S, Fu D, Liu L, Yang D et NPJ Precis Oncol 2026 0
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant [PMID:41720086] Zhao Q, Huang R, Wang C, Hu J, Nie R et Cancer Cell 2026 0
TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, le [PMID:41930604] Yang HC, Deng YS, Zhang J, Zhang T, Song J Alzheimers Dis 2026 0
Hierarchical Targeting of TREM2(+) Myeloid Cells via Acid-Triggered OMVs Reprogr [PMID:41945876] Chen F, Xue Y, Ma X, Chen L, Shao Z et a Adv Sci (Weinh) 2026 0
Correction to "A Strategy Involving Microporous Microneedles Integrated with CAR [PMID:41952643] Unknown Advanced materials (Deerfield 2026 0
TREM2 in neurodegeneration and diseases. [PMID:41792456] ["Abdulkhaliq A", "Alasiri G", "Kim B", Molecular psychiatry 2026 0
Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] Aranda-Abreu GE, Rojas-Durán F, Hernánde Neurology international 2026 0
Molecular mechanism of Alzheimer's disease using integrated multi-omics. [PMID:41907842] Alhusaini M, Mussa BM, Ilce BY, Alhaj H, Frontiers in aging neuroscienc 2026 0
Viral and non-viral cellular therapies for neurodegeneration. [PMID:41585268] ["Srivastav Jyotsna", "Sharma Sachin"] Frontiers in medicine 2025 0
Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. [PMID:20301376] Adam MP, Bick S, Mirzaa GM, Pagon RA, Wa 1993 0